Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Usana Health Sciences (USNA) EBIT Margin (2016 - 2026)

Usana Health Sciences (USNA) has disclosed EBIT Margin for 15 consecutive years, with 0.57% as the latest value for Q3 2025.

  • On a quarterly basis, EBIT Margin fell 722.0% to 0.57% in Q3 2025 year-over-year; TTM through Sep 2025 was 4.58%, a 497.0% decrease, with the full-year FY2024 number at 7.76%, down 234.0% from a year prior.
  • EBIT Margin was 0.57% for Q3 2025 at Usana Health Sciences, down from 7.09% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 57.22% in Q4 2021 to a low of 335750.0% in Q3 2021.
  • A 5-year average of 21383.67% and a median of 8.38% in 2024 define the central range for EBIT Margin.
  • Peak YoY movement for EBIT Margin: tumbled -33576528bps in 2021, then skyrocketed 33576110bps in 2022.
  • Usana Health Sciences' EBIT Margin stood at 57.22% in 2021, then crashed by -124bps to 13.63% in 2022, then surged by 180bps to 10.95% in 2023, then plummeted by -65bps to 3.84% in 2024, then plummeted by -85bps to 0.57% in 2025.
  • Per Business Quant, the three most recent readings for USNA's EBIT Margin are 0.57% (Q3 2025), 7.09% (Q2 2025), and 6.28% (Q1 2025).